You are now leaving our website and heading to a third-party website that we do not operate. We are not responsible for the content of the third-party website. You are advised to review its privacy policy as it may differ from ours.

Are you sure you want to leave?




Explore the pathogenesis and prevalence of secondary hyperparathyroidism (SHPT) in non-dialysis chronic kidney disease (CKD), along with the importance of treating SHPT early, the limitations of current treatments, the guidelines on monitoring and treating SHPT, and the target vitamin D levels for optimal management.

play button icon
camera icon

2:44 mins

Overview of SHPT pathogenesis and the unmet needs in SHPT treatment


25(OH)D: 25-hydroxyvitamin D; CKD: chronic kidney disease; KDIGO: Kidney Disease–Improving Global Outcomes; SHPT: secondary hyperparathyroidism.